Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
Methods and compositions for dengue virus vaccines
US10870682B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10870682-B2 |
| Application number | US-201816105346-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2018 |
| Priority date | Jun 26, 2013 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
First claim
Opening claim text (preview).
That which is claimed is: 1. A chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises the following amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone; wherein the amino acid residue numbering is based on the reference amino acid sequence of an E glycoprotein of dengue virus serotype 3 (DENV3) identified as SEQ ID NO:1: T138S, Q158H, V160T, S169P, A173I, I174Q, P176T, E177D, N272T, G275T, and S277T, and wherein said dengue virus E glycoprotein further comprises an insertion of the amino acid residues T and E between amino acid residues 155 and 156. 2. A flavivirus particle or virus like particle (VLP) comprising the chimeric dengue virus E glycoprotein of claim 1 . 3. A composition comprising the chimeric dengue virus E glycoprotein of claim 1 in a pharmaceutically acceptable carrier. 4. A composition comprising the flavivirus particle or VLP of claim 2 in a pharmaceutically acceptable carrier. 5. A method of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of the chimeric dengue virus E glycoprotein of claim 1 . 6. A method of producing an immune response to a dengue virus in a subject, comprising administering to the subject an effective amount of the flavivirus particle or VLP of claim 2 .
Assignees
Inventors
Classifications
Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Immunomodulators · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10870682B2 cover?
- The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
- Who is the assignee on this patent?
- Univ North Carolina Chapel Hill
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).